OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Shingles vaccine
  2. 2 Can losartan potassium 50 mg daily cause swollen ankles?

Answered on this page ↓

Can losartan potassium 50 mg daily cause swollen ankles?

Oct 20, 2026 · 5 sources used · OpenNeedle synthesis
The short version: losartan is not a typical cause of ankle swelling, but it can cause it in a few specific ways, and one of them is a medical emergency.

Losartan is an ARB, a blood pressure drug. The retrieved records show its common side effects are upper respiratory infection, dizziness, back pain and nasal congestion, not edema [3]. The classic ARB/ACE-inhibitor swelling problem is angioedema, a deeper swelling of lips, tongue or throat, and losartan raises bradykinin, the peptide behind that risk [2]. Angioedema can involve the face and airway, not just the ankles. If swelling comes with lip, tongue or throat swelling or trouble breathing, that is an emergency, not a wait-and-see.

Ankle swelling on losartan usually has another driver. Kidney problems, heart failure, or a second drug like amlodipine are far more common causes. Amlodipine causes dose-dependent ankle edema: 7.5% at 2.5 mg, 13.75% at 5 mg, 28.75% at 10 mg [1]. If you take both, the amlodipine is the likelier culprit.

DrugAnkle edema rate
Amlodipine 2.5 mg7.5% [1]
Amlodipine 5 mg13.75% [1]
Amlodipine 10 mg28.75% [1]
Losartannot listed as common [3]

The retrieval did not surface a losartan-specific edema trial. That gap is real. What it does show: losartan can affect kidney function and potassium handling [4, 5], and kidney problems can cause fluid retention. So the honest answer is that losartan is an uncommon direct cause, but worth checking if swelling is new, one-sided, or comes with breathlessness.

My call: possible but uncommon; check amlodipine, kidney function, and heart failure first, and treat any lip or throat swelling as urgent. Confidence: moderate.

Keep digging

Sources used 5

  1. Comparison of peripheral edema in patient taking 2.5mg, 5mg versus 10mg Amlodipine for hypertension in AIMS Hospital Muzaffarabad AJK Physical Education, Health and Social Sciences (2025) primary study Strong

    In hypertensive patients, higher amlodipine doses were associated with increased incidence and severity of peripheral edema, highest at 10 mg and lowest at 2.5 mg.

    DOI: 10.63163/jpehss.v3i2.386
  2. Losartan Increases Bradykinin Levels in Hypertensive Humans Circulation (2005) Thin

    In hypertensive humans, the AT1 receptor blocker losartan increases arterial bradykinin levels and alters angiotensin peptide metabolism, suggesting a class effect that may contribute to therapeutic actions and angioedema risk.

    DOI: 10.1161/01.cir.0000153269.07762.3b
  3. The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety Cardiovascular Drugs and Therapy (2017) Thin

    This is a comprehensive review synthesizing pharmacogenomic and metabolomic factors that influence the effectiveness and safety of ACE inhibitors and angiotensin II receptor blockers in hypertension, detailing genetic variants, metabolomic markers, epigenomic/proteomic insights,…

    DOI: 10.1007/s10557-017-6733-2
  4. Lithium Toxicity Secondary to Lithium—Losartan Interaction Journal of Pharmacy Technology (2009) other Strong

    A 61-year-old diabetic man with bipolar disorder developed lithium toxicity (peak lithium 2.0 mEq/L) after losartan 50 mg was added to his previously tolerated lithium 1,350 mg/day.

    DOI: 10.1177/875512250902500204
  5. Inhibition of angiotensin type 1 receptor impairs renal ability of K conservation in response to K restriction American Journal of Physiology-Renal Physiology (2009) Thin

    This study investigates the role of angiotensin type 1 receptor (AT1R) in mediating the effects of potassium (K) restriction on renal K conservation, demonstrating that AT1R inhibition impairs the renal ability to conserve K during K depletion by affecting superoxide generation …

    DOI: 10.1152/ajprenal.90725.2008

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →